LabConnect's Strategic Advisory Board: A New Era of Innovation in Healthcare Services
LabConnect, a prominent provider of central laboratory services and functional service provider solutions, has recently revealed the establishment of its Strategic Advisory Board. This significant milestone aims to strengthen LabConnect’s leadership position in the global market while facilitating its commitment to innovation and technology. The members of the board are highly distinguished professionals with extensive backgrounds in pharmaceutical services, clinical development, and laboratory operations.
The inauguration of the Strategic Advisory Board is a strategic move for LabConnect, which seeks to enhance operational efficiency while ensuring transparent and insightful solutions for its clients and partners. Among the respected individuals joining the board are:
Wes Wheeler, the CEO of LabConnect, expressed enthusiasm over the recent appointments, stating, "We are thrilled to welcome Scott, David, and Patrick to our Strategic Advisory Board. Their combined expertise and leadership will be crucial as LabConnect continues to innovate and expand its global presence. This board will play a vital role in helping us deliver exceptional value to our clients and partners."
As LabConnect forges ahead, it remains steadfast in its mission to foster healthier communities by aiding clients in the successful development of new medications for patients worldwide. The formation of the Strategic Advisory Board marks a significant step on this journey, reinforcing LabConnect's status as a trailblazer in the healthcare industry.
LabConnect is recognized as the leading provider of central laboratory services, scientific consulting, and FSP solutions. It specializes in data transformation and integration services for complex analytical and logistical studies, including immuno-oncology, cell and gene therapies, and rare and orphan diseases. With a robust combination of cutting-edge technology, world-class laboratories, and extensive expertise in specialized testing, LabConnect serves as a reliable partner for pharmaceutical development needs. Discover more at www.labconnect.com and follow them on LinkedIn for updates.
Formation of the Board and Appointed Members
The inauguration of the Strategic Advisory Board is a strategic move for LabConnect, which seeks to enhance operational efficiency while ensuring transparent and insightful solutions for its clients and partners. Among the respected individuals joining the board are:
- - Scott Evangelista: With over three decades in pharmaceutical leadership, Scott currently serves as the CEO of Cairn Therapeutics, Inc. He has held pivotal positions in several key organizations, bringing invaluable insight into strategic management and fundraising efforts. His substantial experience in pharmaceutical leadership will be essential in driving LabConnect’s growth and innovative endeavors.
- - David Johnston, Ph.D.: As a Senior Vice President at Thermo Fisher, Dr. Johnston has directed global clinical development following the acquisition of PPD. His wealth of knowledge regarding clinical operations and patient recruitment is expected to enhance LabConnect's ability to increase productivity while reducing clinical development costs.
- - Patrick Hastings: As a seasoned executive with vast experience in the pharmaceutical and clinical laboratory sectors, Patrick was formerly the global vice president at Labcorp, directing central laboratory services. His operational expertise spanning laboratory management and pharmaceutical supply chains will significantly bolster LabConnect’s operational excellence and business performance.
Insights from Leadership
Wes Wheeler, the CEO of LabConnect, expressed enthusiasm over the recent appointments, stating, "We are thrilled to welcome Scott, David, and Patrick to our Strategic Advisory Board. Their combined expertise and leadership will be crucial as LabConnect continues to innovate and expand its global presence. This board will play a vital role in helping us deliver exceptional value to our clients and partners."
As LabConnect forges ahead, it remains steadfast in its mission to foster healthier communities by aiding clients in the successful development of new medications for patients worldwide. The formation of the Strategic Advisory Board marks a significant step on this journey, reinforcing LabConnect's status as a trailblazer in the healthcare industry.
About LabConnect
LabConnect is recognized as the leading provider of central laboratory services, scientific consulting, and FSP solutions. It specializes in data transformation and integration services for complex analytical and logistical studies, including immuno-oncology, cell and gene therapies, and rare and orphan diseases. With a robust combination of cutting-edge technology, world-class laboratories, and extensive expertise in specialized testing, LabConnect serves as a reliable partner for pharmaceutical development needs. Discover more at www.labconnect.com and follow them on LinkedIn for updates.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.